Electroporation therapy for T1 and T2 oral tongue cancer

Landström, Fredrik; Nilsson, Christer; Reizenstein, Johan; Nordqvist, Kent; Adamsson, Gun-Britt; Löfgren, Axel Lennart

doi:10.3109/00016489.2010.541937

Cited by 24 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mucosal reaction to electrochemotherapy differs from cutaneous electrochemotherapy. Previous publications have reported this reaction and our experience concurs with this (Figure ). Primarily, a swelling phase occurs.…”

Section: Resultssupporting

confidence: 92%

The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer

et al. 2018

View full text Add to dashboard Cite

Background Electrochemotherapy is an established treatment for cutaneous tumors. This study aimed at determining efficacy of electrochemotherapy in recurrent head and neck cancer. Methods Phase II clinical trial in patients with recurrent head and neck carcinomas with no curative treatment options. Electrochemotherapy was performed under general anesthesia. Primary endpoint was tumor response (CT scanning) evaluated at week 8. Secondary endpoints included biopsy results, MRI and fluorodeoxyglucose‐positron emission tomography scanning, safety, toxicity, pain score, and quality‐of‐life questionnaires. Results Of 26 patients treated, 5 (19%) achieved complete response, 10 (39%) partial response, resulting in an objective response of 58%. Two responders remain without recurrence. No serious adverse events occurred during treatment. Four events occurred posttreatment: one bleeding episode, two episodes with mucosal swelling, and one patient died due to disease progression. Conclusion Electrochemotherapy is efficient against local recurrence of head and neck cancer with an overall response rate of 58%.

show abstract

Section: Resultssupporting

confidence: 92%

The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The overall appearance of the post-treatment mucosal reaction to calcium electroporation with swelling and necrosis was similar to the one shown with electrochemotherapy. 10,12 Regarding tumor response, a recent trial using electrochemotherapy on 43 patients showed an objective response rate (CR + PR) of 56% with complete response in 19%. 14 Currently, we cannot compare tumor responses between these two electroporation modalities since the calcium data is based on only six patients.…”

Section: Discussionmentioning

confidence: 99%

“…[2][3][4][5] Currently, electroporation is clinically used in combination with chemotherapy, termed electrochemotherapy (ECT). ECT is mainly used on skin tumors and metastases [6][7][8][9] but several studies [10][11][12][13] including a recently published multi-institutional trial 14 have shown that the treatment also can be applied on mucosal head and neck cancers with good tumor response.…”

Section: Introductionmentioning

confidence: 99%

Calcium electroporation for recurrent head and neck cancer: A clinical phase I study

Plaschke

Gehl

Johannesen

et al. 2019

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Background Calcium electroporation is a novel cancer treatment, which combines temporary cell permeability from electroporation with a high influx of calcium intracellularly resulting in cancer cell necrosis. Methods A phase I trial performing calcium electroporation on 6 patients suffering from recurrent head and neck cancer. In general anesthesia, intratumoral calcium injections were followed by electroporation. Safety was monitored by adverse events registration, serum Ca 2+ , ECG, and pain scores. Tumor response was measured on PET/MRI scans. Results Procedures were performed without complications. No serious adverse events, signs of hypercalcemia, or cardiac arrhythmias were observed. Two months post‐treatment tumor responses on MRI: three partial responses, one stable disease, and two progression. Responses on PET: one partial metabolic disease, four with stable metabolic disease, and one not evaluable. One patient was without clinical evidence of disease after 12 months of observation. Conclusion Calcium electroporation is feasible and safe in head and neck tumors. Clinical responses were observed in three of six patients, warranting further studies. Level of Evidence Level 4

show abstract

“…Additionally subsequent studies 11,49,66,[89][90][91][92] of ECT evaluating its effect in the treatment of melanoma and other skin cancers continue to demonstrate the efficacy of the treatment, with response rates comparable to the earlier studies, ranging from 46-100%. Repeated treatments are feasible as demonstrated by Campana et al 90 and Quaglino et al 11 producing additional clinical responses in patients who had initial non or partial responses or who presented with new recurrent lesions.…”

Section: Wwwintechopencommentioning

confidence: 76%